Trending...
- SacraPod Suites Unveils AI-Powered 'Work + Rest' Smart Hospitality Model for Retrofitting Underused Motels Across the U.S
- From Real Estate to Reel Power: H.L Woods Carves His Legacy as a Cutting-Edge Visionary Filmmaker
- WebGlobals Launches Digital Marketing Growth System for Aussie Handyman
Company Selected as 2020 San Diego Cool Company; Industry Veteran Ken Wilke Joins Team to Lead Strategy and Operations for ORP100S Development
SAN DIEGO - AussieJournal -- OrPro Therapeutics announced today that it is expanding its patented technology platform for treatment of acute and chronic airway diseases, including cystic fibrosis (CF), to address the immediate threat posed by COVID-19. In recognition of the broad potential of this approach to address key treatment gaps in airway inflammation and clearance, OrPro has been selected as a 2020 Cool Company (https://connect.org/cool-companies/) by Connect with San Diego Venture Group (SDVG). This year, 296 startups applied for the opportunity to showcase their technology to national venture capital firms and local investors. OrPro is among the elite group of 30 life science companies to be selected.
"We received a record number of applications from extraordinary companies for the 'Cool Companies' program this year," stated Mike Krenn, president and CEO of Connect w/ SDVG. "OrPro and the other finalists truly stand out among the San Diego innovators addressing today's unmet needs."
OrPro Therapeutics is developing ORP100S, a new type of drug to treat inflammation and obstruction in the lung associated with both chronic airway disorders and progression to severe COVID-19 disease caused by SARS-CoV-2 infection. Due to the urgent need to respond to the pandemic, especially for broad-spectrum approaches that overcome many of the limitations of vaccines, antivirals and antibody-based drugs, ORP100S is poised for accelerated COVID-19 clinical development. ORP100S is delivered by inhalation and is planned for home use with the objective of reducing COVID-19 severity and the need for hospitalization.
More on Aussie Journal
To assist in advancing its lead product, ORP100S, pharmaceutical industry veteran Ken Wilke has joined the OrPro Therapeutics management team in a Strategy and Operations leadership role. Ken has over 30 years of experience, including 25 years at Merck, and a proven track record directing strategic initiatives, research and development projects, and operations. He holds a Bachelor of Science in Engineering from Stanford University and a Master of Business Administration from Lehigh University.
"Being chosen as a 2020 Cool Company is a great accomplishment that reflects the hard work of our team to develop a potentially game-changing technology for treatment of respiratory diseases ranging from cystic fibrosis to COVID-19," said Peter B. Heifetz, Ph.D, OrPro President and CEO. "Ken's expertise in research and development, operations, and pharma project management will be critical as we prepare to move ORP100S into the clinic."
OrPro Therapeutics has also been selected to present at the Redefining Early Stage Investments Digital Conference on June 8 – 10. OrPro was chosen for both the RESI Innovation Challenge virtual poster and Featured Company Pitch Session presentation events (https://resiconference.com/resi-calendar/#pitch).
About ORP100S
The ORP100S therapeutic strategy is based on supplementing the activity of the human protein thioredoxin-1 (TXN1), which is normally secreted onto the airway surface where it acts selectively to modify certain types of protein disulfide bonds formed between cysteine amino acids. The thioredoxin mechanism targets airway mucus to keep it at a normal viscosity (thickness and stickiness) and able to maintain the essential process of mucus clearance that sweeps the lungs clean of inhaled material and excess fluid. Thioredoxin also targets regulatory (allosteric) disulfide bonds on immune system proteins as part of a natural homeostatic mechanism to prevent excessive release of cytokines in response to inflammatory stimulus. Together, impaired airway clearance and abnormally elevated cytokine release comprise key pulmonary manifestations of moderate to severe COVID-19 that can lead to systemic disease and poor outcomes.
More on Aussie Journal
Unfortunately, natural thioredoxin is not suitable for delivery as a drug itself because it has a short half-life in the body, low stability in the active form, and needs to be kept on the lung surface to avoid side effects. ORP100S is an improved thioredoxin based on patented technology and optimized for safe, targeted delivery to the site of action in the airway by direct inhalation.
About OrPro Therapeutics
OrPro Therapeutics, Inc is a privately held preclinical-stage company pioneering a novel non-systemic biologic drug platform for treating severe respiratory and mucosal diseases, including cystic fibrosis, COVID-19 and beyond. The company's differentiated approach targets both lung clearance and inflammation as well as obstructive/inflammatory disorders associated with non-respiratory mucosal surfaces in the body. Launched in 2013 with technology in-licensed from National Jewish Health, the company has secured Series A financing and significant non-dilutive grant funding from the National Institutes of Health and the Cystic Fibrosis Foundation with over $5M raised to date. OrPro Therapeutics is a San Diego JLABS resident company (Johnson & Johnson Innovation). For more information visit www.orprotherapeutics.com.
Contact:
Peter Heifetz, Ph.D. OrPro Therapeutics pheifetz@orprotherapeutics.com; 858-242-1557
Media: Joleen Schultz, joleen@joleenschultzassociates.com; 760-271-8150
"We received a record number of applications from extraordinary companies for the 'Cool Companies' program this year," stated Mike Krenn, president and CEO of Connect w/ SDVG. "OrPro and the other finalists truly stand out among the San Diego innovators addressing today's unmet needs."
OrPro Therapeutics is developing ORP100S, a new type of drug to treat inflammation and obstruction in the lung associated with both chronic airway disorders and progression to severe COVID-19 disease caused by SARS-CoV-2 infection. Due to the urgent need to respond to the pandemic, especially for broad-spectrum approaches that overcome many of the limitations of vaccines, antivirals and antibody-based drugs, ORP100S is poised for accelerated COVID-19 clinical development. ORP100S is delivered by inhalation and is planned for home use with the objective of reducing COVID-19 severity and the need for hospitalization.
More on Aussie Journal
- Cover Girl Finalist Teisha Mechetti Questions Legitimacy of Inked Originals Competition, Demands Transparency
- Who to Call When Floods Strike Melbourne: Victoria Hygiene, 24/7
- Easton & Easton, LLP Files Suit Against The Dwelling Place Anaheim & Vineyard USA Over Abuse Allegations
- AI Visibility: The Key to Beating Google's AI Overviews and Regaining Traffic
- Stuck Doing Math or Figuring Out Life's Numbers? Calculator.now Makes It Stupidly Simple
To assist in advancing its lead product, ORP100S, pharmaceutical industry veteran Ken Wilke has joined the OrPro Therapeutics management team in a Strategy and Operations leadership role. Ken has over 30 years of experience, including 25 years at Merck, and a proven track record directing strategic initiatives, research and development projects, and operations. He holds a Bachelor of Science in Engineering from Stanford University and a Master of Business Administration from Lehigh University.
"Being chosen as a 2020 Cool Company is a great accomplishment that reflects the hard work of our team to develop a potentially game-changing technology for treatment of respiratory diseases ranging from cystic fibrosis to COVID-19," said Peter B. Heifetz, Ph.D, OrPro President and CEO. "Ken's expertise in research and development, operations, and pharma project management will be critical as we prepare to move ORP100S into the clinic."
OrPro Therapeutics has also been selected to present at the Redefining Early Stage Investments Digital Conference on June 8 – 10. OrPro was chosen for both the RESI Innovation Challenge virtual poster and Featured Company Pitch Session presentation events (https://resiconference.com/resi-calendar/#pitch).
About ORP100S
The ORP100S therapeutic strategy is based on supplementing the activity of the human protein thioredoxin-1 (TXN1), which is normally secreted onto the airway surface where it acts selectively to modify certain types of protein disulfide bonds formed between cysteine amino acids. The thioredoxin mechanism targets airway mucus to keep it at a normal viscosity (thickness and stickiness) and able to maintain the essential process of mucus clearance that sweeps the lungs clean of inhaled material and excess fluid. Thioredoxin also targets regulatory (allosteric) disulfide bonds on immune system proteins as part of a natural homeostatic mechanism to prevent excessive release of cytokines in response to inflammatory stimulus. Together, impaired airway clearance and abnormally elevated cytokine release comprise key pulmonary manifestations of moderate to severe COVID-19 that can lead to systemic disease and poor outcomes.
More on Aussie Journal
- Colbert Packaging Announces WBENC Recognition
- DivX Empowers Media Enthusiasts with Free Expert Guides for Advanced MP4 Management
- Assent Expands Executive Team to Accelerate Global Growth & Innovation
- The World's Largest Green Economic Revolution Emerges as Nature, Tech, and Finance Converge
- Vinnetwork Unveils Decentralized AI Platform with Vinnetwork(VIN) Token to Challenge Tech Giants' Data Monopoly
Unfortunately, natural thioredoxin is not suitable for delivery as a drug itself because it has a short half-life in the body, low stability in the active form, and needs to be kept on the lung surface to avoid side effects. ORP100S is an improved thioredoxin based on patented technology and optimized for safe, targeted delivery to the site of action in the airway by direct inhalation.
About OrPro Therapeutics
OrPro Therapeutics, Inc is a privately held preclinical-stage company pioneering a novel non-systemic biologic drug platform for treating severe respiratory and mucosal diseases, including cystic fibrosis, COVID-19 and beyond. The company's differentiated approach targets both lung clearance and inflammation as well as obstructive/inflammatory disorders associated with non-respiratory mucosal surfaces in the body. Launched in 2013 with technology in-licensed from National Jewish Health, the company has secured Series A financing and significant non-dilutive grant funding from the National Institutes of Health and the Cystic Fibrosis Foundation with over $5M raised to date. OrPro Therapeutics is a San Diego JLABS resident company (Johnson & Johnson Innovation). For more information visit www.orprotherapeutics.com.
Contact:
Peter Heifetz, Ph.D. OrPro Therapeutics pheifetz@orprotherapeutics.com; 858-242-1557
Media: Joleen Schultz, joleen@joleenschultzassociates.com; 760-271-8150
Source: OrPro Therapeutics
0 Comments
Latest on Aussie Journal
- BIYA Forecasts 2025 Surge with ¥300M ($41.8 M USD) in Revenue and ¥25M Profit from Cloud Based HR Solutions: Baiya Intl. Group (N A S D A Q: BIYA)
- Paul E. Saperstein Co. Announces Geographic Expansion of Auction Services
- Florida Broker Bent Danholm Featured in the Daily Mail's U.S. Real Estate Coverage
- Robin Launches Legal Intelligence Platform to solve intelligence gap in Fortune 500 legal teams
- Melissa B. Releases Digitally Independent: Empowering Music Artists with AI and Brand Strategy
- Consumer Accountability Alliance Issues Formal Notice Alleging Proximate Liability for Medical Harm
- A consortium of investors purchases the specialised plastic fabrication business, Viking Plastics
- Utah Metal Fabricator Titan Forge Builds Momentum with Custom Steel Projects and Spiral Staircases
- Jason Koch: Pioneering the Future of Real Estate Development in New Jersey
- Bach and Beyond: Cellists Return to the Beach for 2nd Annual Bethany Beach Cellofest
- NR7 Miner launches zero-cost USDT cloud mining service: daily stable income + referral rewards for double profit
- Deaths Spur Closures, but Troubled Teen Camps Must Be Banned, CCHR Warns
- Palmer Lake Wine Festival To Build Bridges in Small Mountain Community, Highlight Local Businesses
- Transform Your Home Comfort with the Daikin US7 – Professionally Installed by Melbourne Aircon
- WebGlobals Launches Digital Marketing Growth System for Aussie Handyman
- SacraPod Suites Unveils AI-Powered 'Work + Rest' Smart Hospitality Model for Retrofitting Underused Motels Across the U.S
- From Real Estate to Reel Power: H.L Woods Carves His Legacy as a Cutting-Edge Visionary Filmmaker
- ABN or TFN? Nanak Accountants Clarifies Australia's Tax Identity System for Workers and Business
- ATO Reminds Australians to Get WFH Tax Claims Right, Nanak Accountants Offers Expert Support
- New Release: 'The Invisible Alternative' Unveiled by Atrisk Corporation, Resilient